What is Pyribenzamin used for?

Pyribenzamin is indicated for Allergic conjunctivitis, Allergic rhinitis, Anaphylaxis Adjunct, Dermatographic urticaria, Itching of skin.

Who makes Pyribenzamin?

Pyribenzamin is developed by Novartis.

What development phase is Pyribenzamin in?

Pyribenzamin is FDA-approved (marketed).

What is the generic name of Pyribenzamin?

TRIPELENNAMINE CITRATE is the generic (nonproprietary) name of Pyribenzamin.

Last reviewed 2026-04-20 · How we verify

Pyribenzamin (TRIPELENNAMINE CITRATE)

Novartis · FDA-approved approved Small molecule Quality 27/100

At a glance

Generic name	TRIPELENNAMINE CITRATE
Sponsor	Novartis
Drug class	tripelennamine
Target	Histamine H1 receptor
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved
First approval	1948

Approved indications

Allergic conjunctivitis
Allergic rhinitis
Anaphylaxis Adjunct
Dermatographic urticaria
Itching of skin
Nasal congestion
Nasal discharge
Sneezing
Urticaria
Vasomotor rhinitis

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pyribenzamin CI brief — competitive landscape report
Pyribenzamin updates RSS · CI watch RSS
Novartis portfolio CI